Precision T-cell treatment slows resistant cancers in early clinical trial results
-
October 23, 2026
-
1
In phase 1 and early phase 2 testing, invikafusp alfa selectively stimulated two groups of tumor-infiltrating T cells in patients with advanced cancers.
-
2
Among 27 participants treated at the optimal dose, 16 (59.3%) had no disease progression and 4 (14.8%) had tumor reductions exceeding 30%.
-
3
Tumor shrinkage occurred in two patients with metastatic colorectal cancer and one with stage 4 non-small cell lung cancer, all resistant to prior treatments.
-
4
At the optimal dose, invikafusp alfa was generally well tolerated; reported flu-like effects were typically manageable with medication and supportive care.
-
5
The investigators described the results as preliminary and said immune activation did not always produce a measurable clinical response.
Based on findings from:
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
National Institutes Of Health, 2026.
https://www.nih.gov/news-events/news-releases/precision-t-cell-therapy-stalls-treatment-resistant-cancers-clinical-trial
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
